Literature DB >> 10408491

Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.

T Müller, B Werne, B Fowler, W Kuhn.   

Abstract

We found increased levels of atherosclerosis-inducing homocysteine in parkinsonian patients with long-term application of levodopa compared with previously untreated parkinsonian patients and controls. We conclude that antiparkinsonian treatment with levodopa promotes occurrence of vascular disease in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10408491     DOI： 10.1016/s0140-6736(99)01660-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  26 in total

1.  Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

2.  The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Authors:  E Nissinen; H Nissinen; H Larjonmaa; A Väänänen; T Helkamaa; I Reenilä; P Rauhala
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

3.  Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

Authors:  D Caccamo; G Gorgone; M Currò; G Parisi; W Di Iorio; C Menichetti; V Belcastro; L Parnetti; A Rossi; F Pisani; R Ientile; P Calabresi
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

5.  Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.

Authors:  Carlos Enrique Orozco-Barrios; Shyue-Fang Battaglia-Hsu; Martha Ligia Arango-Rodriguez; Jose Ayala-Davila; Celine Chery; Jean-Marc Alberto; Henry Schroeder; Jean-Luc Daval; Daniel Martinez-Fong; Jean-Louis Gueant
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 6.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

7.  Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Authors:  Martin Nevrly; Petr Kanovsky; Hana Vranova; Katerina Langova; Petr Hlustik
Journal:  Neurol Sci       Date:  2010-05-13       Impact factor: 3.307

Review 8.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 10.  Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.

Authors:  Daniel D Truong
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.